Alnylam Pharmaceuticals Inc (ALNY)

235.80 +2.65 (+1.14%) USD  |  NASDAQ  |  Jan 07, 16:00
235.80 0.00 (0.00%) After-Hours: 16:16
More

Alnylam Pharmaceuticals Research and Development Expense (Annual): 1.004B for Dec. 31, 2023

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Pfizer Inc 10.68B
BridgeBio Pharma Inc 455.71M
Gilead Sciences Inc 5.718B
Sarepta Therapeutics Inc 877.39M
Regeneron Pharmaceuticals Inc 4.439B